Top Markets
Coin of the day
PCL, Inc. PCL, Inc.

PCL, Inc.

241820
주식 순위 #31791
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic... PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
주가
$0.21291741
마지막 동기화: 2025-04-18
시가총액
$12.07M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
KR
거래 PCL, Inc. (241820)

카테고리

PCL, Inc. (241820)의 P/B 비율
August 2026 기준 P/B 비율 TTM: 0.31
PCL, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0.31입니다. 2023년 말 기준 P/B 비율은 4.33였습니다.
PCL, Inc.의 P/B 비율 기록 (2015 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 0.31 -92.92%
2024 4.37 0.92%
2023 4.33 -22.84%
2022 5.61 -79.76%
2021 27.74 158.91%
2020 10.71 -23.63%
2019 14.03 43.20%
2018 9.80 -11.87%
2017 11.12 -9.46%
2016 12.28 -33.14%
2015 18.36 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
3.7944 1,126.37%
US
5.423 1,652.75%
US
2.0146 551.13%
IE
3.072 892.89%
US
4.9725 1,507.14%
US